9503 Background: Pathological complete response (pCR) to neoadjuvant systemic therapy
(NST) correlates with survival, and is recognized as a path to regulatory approval in several …

Abstract During the European Cancer Congress, the melanoma sessions focused on
practice changing trials. Recent developments and approvals in immunotherapy and …

Patients with melanoma who have regional nodal or intransit involvement at diagnosis
(stage III) are at a high risk for recurrence, with the 5-year survival ranging from 93% for IIIA …

9502 Background: Neoadjuvant therapy (NT) for pts with clinical stage III melanoma remains
an active area of research interest. Recent NT trial data demonstrates that achieving a …

Tremendous progress has been made in treating patients with metastatic melanoma over
the past decade. In that timeframe, the FDA has approved 12 novel treatments for patients …

Clinical trials of neoadjuvant therapy for melanoma have expanded rapidly over the past
several years. Preliminary data demonstrate the prognostic value of pathological response …

Neoadjuvant immunotherapy is gathering pace, particularly in melanoma. A recent study of
pembrolizumab and HDI not only further supports the safety and activity of neoadjuvant anti …

TPS10088 Background: Recent clinical trials of neoadjuvant (neo-adj) ipilimumab combined
with nivolumab (OpACIN & OpACIN-neo) in resectable stage III melanoma show that a …

The treatment of advanced melanoma has significantly changed since the development of
targeted and immune therapy. To date, these agents have primarily been used in the …

Introduction: The aim of this work is to discuss the role of neoadjuvant therapy in melanoma
patients, namely the potential to improve control and surgical resectability of locoregional …